High Mobility Group 20B (HMG20B) (Middle Region) Peptid
HMG20B
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN978045
Kurzübersicht für High Mobility Group 20B (HMG20B) (Middle Region) Peptid (ABIN978045)
Target
HMG20B
(High Mobility Group 20B (HMG20B))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-HMG20B antibody (Catalog #: ARP35798_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- HMG20B (High Mobility Group 20B (HMG20B))
-
Hintergrund
-
HMG20B is required for correct progression through G2 phase of the cell cycle and entry into mitosis. HMG20B is also required for RCOR1/CoREST mediated repression of neuronal specific gene promoters.
Alias Symbols: BRAF25, BRAF35, FLJ26127, HMGX2, PP7706, SMARCE1r, SOXL, pp8857, HMGXB2
Protein Interaction Partner: BRCA2,CCDC85B,HNRNPL,KIF4A,PHF21A,TACC2,VIM,BRCA2,CCDC85B,HDAC1,HDAC2,HNRNPL,KDM1A,KIF4A,PHF21A,RCOR1,SF3A2,TACC2,VIM
Protein Size: 317 -
Molekulargewicht
- 37 kDa
-
Gen-ID
- 10362
-
NCBI Accession
- NM_006339, NP_006330
-
UniProt
- Q9P0W2
Target
-
Sie sind hier:
